More recently, an analysis of a French registry cohort has shown an incidence of BTK mutations of 57% in patients who were still on ibrutinib, suggesting that a substantial proportion of patients with CLL on ibrutinib monotherapy already harbors resistance-conferring mutations when clinically still responding to treatment [34]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.